

Why consider universal nasal decolonization for all patients?

Improve Patient Safety

Universal nasal decolonization has been shown to reduce the incidence of healthcare-associated infections (HAIs) and improve clinical outcomes when added to existing infection prevention bundles.

According to the CDC, pathogens that cause HAIs can be transmitted through direct or indirect contact from both asymptomatically colonized and symptomatically infected patients. Universal nasal decolonization helps create a safer environment for all patients by reducing the overall bacterial burden in the hospital and potential for transmission.¹

Evidence-Based Practice

Evidence supports the role of universal decolonization as an effective and efficient strategy to reduce the risk and incidence of HAIs across diverse settings and wide-ranging patient populations. Universal nasal decolonization protocols using alcohol-based Nozin® Nasal Sanitizer® antiseptic have been proven to successfully reduce HAIs.^{2,3,4,5}

Clinical expertise recognizes that the benefits of universal decolonization include:⁶

- Reduced risk of infection in colonized patients
- Lower risk of transmission from colonized patients and helping to protect uncolonized individuals


It is evident that reducing nasal colonization by use of an antiseptic may be a potent strategy to prevent antimicrobial-resistant infections. Preventing HAIs enhances patient outcomes, avoids excess length of stay and improves throughput. These are key to better hospital operations and return on investment (ROI).

The Nozin company is at the forefront of nasal decolonization care and helping hospitals ensure successful programs.



Nozin®

Protect Every PatientSM



At Nozin, our core **Protect Every PatientSM** service mission is to help hospitals decrease avoidable HAIs. Universal nasal decolonization with **Nozin NOVASM** programs powered by **Nozin[®] Nasal Sanitizer[®]** antiseptic as part of a comprehensive infection prevention strategy has been shown to reduce HAIs. With evidence-based support for better patient outcomes, this standard of care helps reduce pathogen burden, lower potential for transmission and create a safer environment. The associated benefits to hospital operations can include improved throughput and significant cost savings.

Proprietary Tools

- ✓ Customized program often including detailed ROI analysis
- ✓ Customized colonization risk profile analysis

Expert Help

- ✓ Clinical support
- ✓ Program design
- ✓ Internal buy-in support

Implementation Support

- ✓ Policy and procedure templates
- ✓ IT consultation
- ✓ Access to corporate implementation team

Continued Support

- ✓ Ongoing support after your go-live date
- ✓ Compliance reviews



Scan to learn more.
Nozin.com

Nozin[®]

©2024 Global Life Technologies Corp. All rights reserved. Made in USA. Nozin[®], Nasal Sanitizer[®], Popswab[®], Protect Every PatientSM, and NOVASM are trademarks of Global Life Technologies Corp. Nozin[®] Nasal Sanitizer[®] antiseptic is used for antiseptic skin preparation and helps reduce bacteria that can cause skin infections. To request references: nozin.com/clinical-outcomes. The clinical studies presented evaluate the impact of nasal decolonization using an alcohol-based nasal antiseptic within existing infection prevention and control (IPC) programs. Nasal decolonization is one component of a multifaceted approach to infection prevention and control. The addition of nasal decolonization should be viewed as complementary to existing protocols designed to enhance the overall effectiveness of IPC programs. Reported outcomes reflect the impact of nasal decolonization when integrated into established IPC practices. Results may vary depending on the specific combination of interventions employed, adherence to protocols, and other factors unique to each healthcare setting. Healthcare providers should consider nasal decolonization as part of a holistic approach to IPC. Implementation of any new IPC measure should align with institutional policies, current clinical guidelines, and regulatory requirements. Patent nos.: nozin.com/patents.

1. Mangalea MR, Halpin A, Haile M, et al. (2024). Emerging Infectious Diseases, 30(6), 1069-1076. <https://doi.org/10.3201/eid3006.231338>. 2. Klemm, A. (2024). American Journal of Infection Control, Volume 52, Issue 6, 575 <https://doi.org/10.1016/j.ajic.2024.04.145>. 3. Montalvo Gonzalez, L., Macedo-Rea, M., Manos, O., et al. (2023). American Journal of Infection Control, Volume 51, Issue 7, 554 <https://doi.org/10.1016/j.ajic.2023.04.111>. 4. Jimenez, A., Sposato, K., et al. (2019). Open Forum Infectious Diseases, 6(S2), S268. 5. Hoffmann, Karen K. et al. (2024). American Journal of Infection Control, Volume 52, Issue 0, 1202 - 1208. <https://doi.org/10.1093/ofid/ofz360.635>. 6. Mangalea MR, Halpin A, Haile M, et al. (2024). Emerging Infectious Diseases, 30(6), 1069-1076. <https://doi.org/10.3201/eid3006.231338>.